Advantage Alpha Capital Partners LP Crinetics Pharmaceuticals, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 8,640 shares of CRNX stock, worth $437,702. This represents 0.11% of its overall portfolio holdings.
Number of Shares
8,640Holding current value
$437,702% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.5MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$319 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$316 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$298 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$251 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$226 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.72B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...